Discontinuation of tyrosine kinase therapy in CML

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 187-193

  Mahon, Francois Xavier ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic myeloid leukemia; Deep molecular response; Treatment free remission

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CONSOLIDATION CHEMOTHERAPY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOSURVEILLANCE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REMISSION;

ANTINEOPLASTIC AGENTS; DRUG MONITORING; FUSION PROTEINS, BCR-ABL; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION;

EID: 84925945641     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2320-4     Document Type: Review

References (44)

1. National Comprehensive Cancer Network (2012) Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology; v1.2013
2. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884
3. Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX (2012) Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7:103–108
4. Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58–60
5. Mahon FX (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematol Am Soc Hematol Educ Program 2012:122–128
6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035
7. Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE et al (2013) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM Study. Blood (ASH Annual Meeting Abstracts);122, [abstract 255]
8. Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719–1724
9. Ross DM, Branford S, Seymour JF, Arthur C, Schwarer AP, Dang P et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522
10. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903–906
11. Cortes J, O’Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204–2205
12. Mauro MJ, Druker BJ, Marziaz RT (2004) Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(S1):S71–S73
13. Merante S, Orlandi E, Bernasconi P et al (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979–981
14. Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267–1270
15. Mahon FX, Nicolini F, Noël MP, Escoffre M, Charbonnier A, Rea D, Dubruille V, Varet B, Legros L, Guerci A, Etienne G, Guilhot F, Dulucq S, Rousselot P, Guilhot J (2013) Preliminary Report Of The STIM2 Study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts) [abstract 654]
16. Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424–430
17. Saussele S, Richter J, Guilhot J, Müller MC, Dietz C, Porkka K et al (2014) First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. 19th Congress of the European Hematology Association, Milan, Italy, June 12–15, 2014. Haematologica 99(supl. 1):LB-6214
18. Mahon FX, Baccarani M, Mauro M et al (2014) Treatment-free remission following nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath ASCO meeting 2014. J Clin Oncol 32:5s, (suppl; abstr TPS7124)
19. Stein AM, Bottino D, Modur V et al (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 21:6812–6821
20. Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I (2013) Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121:378–384
21. Cross NCP, White H, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175
22. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080–7085
23. Melo JV, Ross DM (2011) Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematol Am Soc Hematol Educ Program 2011:136–142
24. Biernaux C, Loos M, Sels A et al (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 8:3118–3122
25. Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362–3367
26. Deininger M (2011) Hematology: curing CML with imatinib—a dream come true? Nat Rev Clin Oncol 3:127–128
27. Réa D, Rousselot P, Nicolini F, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F, Mahon FX (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FI-LMC) Blood (ASH) 2012: Abstract 9168. Rea D, et al. Blood.;118(21) [abstract 604]
28. Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S et al (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36:689–693
29. Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818–3824
30. Falchi L, Kantarjian HM, Wang X et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024–1029
31. Hehlmann R, Müller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415–423
32. Rea D, Dulphy N, Henry G, J Guilhot J, Guilhot F, Franck E. Nicolini, Legros L, Rousselot Ph, Mahon FX, Toubert A (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators. Blood (ASH Annual Meeting Abstracts); 122 (suppl): abstract 856
33. Ilander MM, Olsson-Strömberg U, Lähteenmäki H et al (2013) Disease Relapse After TKI Discontinuation in CML is related both To low number and impaired function of NK-cells: data from Euro-SKI. Blood (ASH Annual Meeting Abstracts); 122 (suppl): abstract 379
34. Mahon FX, Delbrel X, Cony-Makhoul P et al (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214–220
35. Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1–7
36. Gallipoli P, Abraham SA, Holyoake TL (2011) Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin N Am 25:951–966
37. Rea D, Rousselot P, Guilhot J et al (2012) Curing chronic myeloidleukemia. Curr Hematol Malignancy Rep 7:103–108
38. Hantschel O, Warsch W, Eckelhart E et al (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285–293
39. Chen Y, Peng C, Sullivan C et al (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anti Cancer Agents Med Chem 10:111–115
40. Zhang B, Strauss AC, Chu S et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17:427–442
41. Li L, Wang L, Li L et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266–281
42. Hurtz C, Hatzi K, Cerchietti L et al (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208:2163–2174
43. Kleppe M, Levine RL (2012) Targeting beta-catenin in CML: leukemiastem cells beware! Cell Stem Cell 10:351–353
44. Dierks C, Beigi R, Guo GR et al (2008) Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238–249